Apigenin, a common dietary¯avonoid abundantly present in fruits and vegetables, may have the potential for prevention and therapy for prostate cancer. Here, we report for the ®rst time that apigenin inhibits the growth of androgen-responsive human prostate carcinoma LNCaP cells and provide molecular understanding of this eect. The cell growth inhibition achieved by apigenin treatment resulted in a signi®cant decrease in AR protein expression along with a decrease in intracellular and secreted forms of PSA. These eects were also observed in DHT-stimulated cells. Further, apigenin treatment of LNCaP cells resulted in G1 arrest in cell cycle progression which was associated with a marked decrease in the protein expression of cyclin D1, D2 and E and their activating partner cdk2, 4 and 6 with concomitant induction of WAF1/p21 and KIP1/p27. The induction of WAF1/p21 appears to be transcriptionally upregulated and is p53 dependent. In addition, apigenin inhibited the hyperphosphorylation of the pRb protein in these cells. Apigenin treatment also resulted in induction of apoptosis as determined by DNA fragmentation, PARP cleavage,¯uorescence microscopy and¯ow cytometry. These eects were found to correlate with a shift in Bax/Bcl-2 ratio more towards apoptosis. Apigenin treatment also resulted in down-modulation of the constitutive expression of NF-kB/p65. Taken together, these ®ndings suggest that apigenin has strong potential for development as an agent for prevention against prostate cancer.
Introduction
For prevention and treatment of prostate cancer, development of novel agents present in fruits and vegetables consumed by humans is a desirable goal. Apigenin (4',5,7,-Trihydroxy¯avone; Figure 1 ), one of the most common¯avonoids, is widely distributed in many fruits and vegetables, including parsley, onions, orange, tea, chamomile, wheat sprouts and in some seasonings (Birt et al., 1998; Duthie and Crozier, 2000) . Apigenin has been shown to possess anti-in¯ammatory, and anti-carcinogenic eects for skin and free radical scavenging properties in many in vitro systems (Kim et al., 1998) . Studies have shown that apigenin possesses growth inhibitory properties against many human cancer cell lines, including breast (Yin et al., 2001) , colon (Wang et al., 2000) , skin (Caltagirone et al., 2000) , thyroid (Yin et al., 1999) , leukemia cells (Takahashi et al., 1998) , and solid malignant tumor cells (Fotsis et al., 1998) . Apigenin has been found to be anti-mutagenic against nitropyrene-induced genotoxicity in Chinese hamster ovary cells (Kuo et al., 1992) . Apigenin has been reported to inhibit mitogen activated protein kinase and the downstream oncogenes in v-Ha-ras-transformed NIH3T3 cells (Kuo et al., 1994) . Studies have also shown that apigenin is a strong inhibitor of ornithine decarboxylase activity, an enzyme playing a major role in tumor promotion (Wei et al., 1990) . Furthermore, apigenin has been shown to increase gap junctions in rat epithelial cells, a property that may also contribute to its chemopreventive ability by maintaining cell ± cell communication (Chaumontet et al., 1994) . Apigenin under in vivo conditions has been shown to inhibit tumor necrosis factor-induced intercellular adhesion molecule-1 upregulation (Panes et al., 1996) . Exposure of apigenin prior to carcinogenic insult has been shown to aord protective eect in murine skin model systems (Wei et al., 1990; Birt et al., 1997) . More recently, apigenein has been shown to induce a reversible G2/M arrest in both epidermal cells and ®broblast by inhibition of p34 cdc2 kinase activity (Lepley et al., 1996; Lepley and Pelling, 1997) . A recent study has shown that apigenin is a potent inhibitor of the activation of nuclear transcription factor NF-kB, which has been implicated to play a key role in the regulation of cell growth, cell-cycle regulation, and apoptosis (Liang et al., 1999) .
Our recent data, demonstrating that apigenin causes selective cell cycle arrest and apoptosis of several human prostate carcinoma cells but not of normal cells (Gupta et al., 2001) , oers promise for the use of apigenin for prevention and therapy of prostate cancer. Extending these studies, here, for the ®rst time, we show that apigenin decreases intracellular and secreted levels of PSA in androgen-responsive human prostate carcinoma LNCaP cells under both serum-and androgen-stimulated conditions, with concomitant inhibition of AR and cell growth via a G1 arrest during cell cycle progression. The G1 arrest by apigenin leads to the stabilization of p53 and downmodulation of pRb phosphorylation. These events were associated with alterations in the levels of Bax and Bcl-2 shifting the Bax : Bcl-2 ratio more towards apoptosis along with inhibition of NF-kB/p65.
Results

Apigenin decreases serum-and DHT-stimulated AR and PSA expression in LNCaP cells
Evidence suggests that androgens are also involved in the development and progression of prostate cancer where AR is the essential mediator for androgen action (Lamb et al., 2001; Wang et al., 1997) . We therefore, ®rst determined the eect of apigenin on the AR protein expression. Treatment of LNCaP cells with apigenin resulted in a signi®cant decrease in the AR protein expression at 20 mM concentrations (Figure 2a ). In the time-dependent study however, a modest decrease in the AR protein expression was observed up to 72 h of treatment with 10 mM apigenin. In DHTstimulated cells a slight decrease in the AR protein expression was observed at the highest concentration of 100 nM (Figure 2b) .
Recent studies have shown that modulation in AR leads to alteration in androgen-responsive genes (Naz and Herness, 2001) . One of the androgen-responsive gene is prostate-speci®c antigen (PSA), which is speci®cally expressed, in prostatic tissue and at present is the most sensitive biomarker and screening tool for prostate cancer in humans (Stamey et al., 1987) . The LNCaP cells grown in 10% FBS exhibit high protein levels of intracellular PSA as evidenced by a 34-KD band. The dose-dependent eect of apigenin on LNCaP cells exhibited a signi®cant decrease in PSA protein levels by 46, 61, 70, and 73% at 1, 5, 10 and 20 mM concentration (Figure 2c) . Similarly, cells grown in 10% FBS with 10 mM concentration of apigenin exhibited a signi®cant decrease in PSA protein levels by 59, 72 and 78% observed at 24, 48 and 72 h, respectively (Figure 2c ).
Because promoter of PSA gene contains functional androgen-responsive elements (Wang et al., 1997) , and DHT up-regulates AR protein expression as well as PSA production in LNCaP cells, we next examined the eect of apigenin on PSA levels. The cells were grown in charcoal-stripped serum with varying concentrations of DHT. Incubation of LNCaP cells with increasing concentrations of DHT lead to an increase in protein expression of PSA, which was signi®cantly reduced by treatment with 10 mM concentration of apigenin ( Figure 2d ).
We next examined the eect of apigenin on secreted levels of PSA in LNCaP cells grown in 10% FBS. Treatment of cells with apigenin resulted in a signi®cant decrease in the secreted levels of PSA by 41, 53, 60 and 66% at 1, 5, 10 and 20 mM concentration ( Figure 3a) . Similarly, cells grown in 10% FBS and treated with 10 mM concentration of apigenin exhibited a signi®cant decrease in 24, 48, 68% at 24, 48 and 72 h (Figure 3a) . The DHT-stimulated cells leads to an increase in intracellular levels of PSA ( Figure 3b ) and secreted PSA levels in the culture medium (data not shown), which was signi®cantly reduced by treatment with 10 mM concentration of apigenin ( Figure 3b ). Taken together, the inhibitory eects of apigenin on FBS-and DHT-stimulated LNCaP cell growth were consistent with a decrease in AR protein expression and both intracellular and secreted PSA levels.
Apigenin induces cell growth inhibition in LNCaP cells
The MTT assay demonstrated that apigenin (1 ± 80 mM) treatment, resulted in a dose-dependent inhibition of LNCaP cell growth, as compared to untreated controls (Figure 4 ). Apigenin treatment also resulted in timedependent inhibition of cell growth. This eect was more pronounced at 48 and 72 h post-treatment (Figure 4) . The inhibition of cell growth could be a result of the induction of apoptosis that may be mediated by cell cycle growth arrest. We, therefore, hypothesized that apigenin-mediated cell growth inhibitory eects may be due to perturbation in cell cycle that may possibly lead to programmed cell death.
Apigenin induces G1 cell cycle arrest and alterations in G1 cell cycle regulatory proteins in LNCaP cells
Treatment of LNCaP cells with apigenin resulted in a dose-dependent inhibition of cell growth as compared with their untreated controls at all the time points observed. We considered the possibility that this may involve an arrest of cells at speci®c check point(s) in the cell cycle. We therefore assessed the eect of Figure 1 Structure of apigenin, a common¯avonoid present in fruits and vegetables. Apigenin consists of a benzene ring (a) fused with a six-member ring that in position 2 carries a phenyl ring (b) as a substituent Apigenin induced cell-cycle regulation and apoptosis S Gupta et al apigenin on cell cycle perturbations. The cells were synchronized by serum deprivation for 36 h and later incubated with 10% FBS with varying concentrations of apigenin for 24 h. Compared with the vehicletreated controls, apigenin treatment resulted in an appreciable arrest of cells in G0 ± G1 phase of cell cycle after 24 h of the treatment. The treatment caused an arrest of 75% cells in G0 ± G1 phase of the cell cycle at 1 mM concentration that further increased to 80% at 5-mM, 84% at 10 mM and 89% at the highest dose of 20 mM in these cells ( Figure 5 ). This increase in G0 ± G1 cell population was accompanied with a concomitant decrease of cell number in S phase and G2-M phase of the cell cycle ( Figure 5 ). Next, we assessed the protein expression of the cyclins and cdks, which are known to be operative in G1-phase to investigate if their function is altered. Treatment of LNCaP cells with apigenin resulted in a dose-dependent decrease in the protein expression of cyclins D1, D2 and E (Figure 6a ). The decrease in cyclin D1 protein expression was more pronounced than that of cyclin D2 and cyclin E. Similar timedependent inhibition was observed in cyclins D1, D2 and E after treatment of cells with 10 mM concentration of apigenin for 24, 48 and 72 h (Figure 6a ).
The eect of apigenin was also observed in the protein levels of cdks. Treatment of LNCaP cells with apigenin resulted in a dose-dependent decrease in cdk2, 4 and 6 (Figure 6b ). The decrease in cdk2 protein expression was more pronounced than that of cdk4 and cdk6. Similar time-dependent inhibition was observed in cdk2, 4 and 6 after treatment of cells with 10 mM concentration of apigenin for 24, 48 and 72 h (Figure 6b ). The decrease in the protein expression of cdk6 was much more pronounced at 48 and 72 h than at 24 h post-apigenin treatment (Figure 6b ).
We next assessed the eect of apigenin treatment on the induction of WAF1/p21, which is known to regulate the entry of cells at G 1 ?S transition checkpoint. Western blot analysis revealed that apigenin treatment results in appreciable induction of WAF1/p21 even at the lowest concentration of 1 mM with a signi®cant increase at the high concentration of 20 mM. Similarly, 10 mM apigenin treatment resulted in a signi®cant induction of WAF1/p21 at 24, 48, and 72 h after the treatment, when compared with the basal levels ( Figure 6c ). We also estimated the protein levels of KIP1/p27 after treatment with apigenin. As shown in Figure 6c , treatment of apigenin resulted in a dosedependent induction of KIP1/p27 and was maximum at the highest concentration of 20 mM. Further, Western blot analysis revealed that apigenin treatment resulted in a signi®cant induction of KIP1/p27 at 24 and 48 h with diminished protein levels at 72 h after the treatment, compared with the basal levels ( Figure  6c ).
Apigenin stabilizes p53 protein expression and inhibits Rb phosphorylation in LNCaP cells
Employing Western blot analysis, we next assessed the protein expression of p53 that is also known to play an important role in cell cycle regulation. Since LNCaP cells harbor wild-type p53, we studied the eect of apigenin on the protein expression of p53 in these cells. As shown in Figure 7 , apigenin treatment resulted in a dose-dependent accumulation in p53 protein expression in LNCaP cells, which was more pronounced at concentration of 10 and 20 mM. The time-dependent treatment with 10 mM concentration of apigenin resulted in the stabilization of p53 protein, which was observed up to 72 h post-treatment compared to the basal levels ( Figure 7) .
Another key regulator of the G1?S phase transition in the cell cycle is the retinoblastoma (pRb) tumor suppressor protein (Adams, 2001) . The protein product of the retinoblastoma gene, pRb is a nuclear phosphoprotein that controls the cells during the G1 phase of the cell cycle by repressing transcription of genes required for the G1?S phase transition (Ahmad et al., 1999) . Studies have demonstrated the pRb is phosphorylated in a cell-cycle dependent manner and that progression of cell through G1?S transition requires inactivation of pRb by phosphorylation (Adams, 2001; Ahmad et al., 1999) . As shown in Figure 7 , apigenin treatment resulted in a signi®cant dose-dependent decrease in the protein expression of hyper-phosphorylated form of ppRb and this was accompanied with a concomitant increase in the hypophosphorylated form of pRb. Similar observations were observed with time-dependent study where the cells were treated with 10 mM concentration of apigenin for 24, 48 and 72 h. In subsequent experiment, employing a phospho-speci®c antibody we evaluated the eect of apigenin treatment on serine 780 phosphorylation of pRb. As shown in Figure 7 , apigenin treatment resulted in dose-as well as timedependent decrease in serine-780 phosphorylation of pRb in these cells.
Apigenin induces apoptosis in LNCaP cells
In the next series of experiments we assessed the eect of apigenin treatment on apoptosis in LNCaP cells. The cells were treated with varying concentration of apigenin (1 ± 20 mM). As shown in Figure 8a , compared with vehicle-treated control, apigenin treatment (10 and 20 mM for 48 h) resulted in the formation of DNA fragments in LNCaP cells. Similarly, treatment with 10 mM concentration of apigenin resulted in the formation of DNA ladder at 48, and 72 h posttreatment. Additionally, PARP cleavage analysis showed that the full size PARP (116 KD) protein was cleaved to yield an 85 KD fragment after treatment of cells with apigenin at 10 and 20 mM concentrations ( Figure 8b ). The time-dependent eect of apigenin treatment was almost similar to that of DNA fragmentation where 10 mM concentration of apigenin resulted in the cleavage of PARP at 48 and 72 h post-treatment ( Figure 8b ). The induction of apoptosis by apigenin was also evident from the morphology of cells as assessed by¯uorescence microscopy after labeling the cells with annexin V Figure 8c ). We used this method because it identi®es the apoptotic (green¯uorescence) as well as necrotic (red¯uorescence) cells. As shown by data in Figure 8c , apigenin treatment resulted in a dose-dependent apoptosis in LNCaP cells. These data indicated that apigenin treatment also resulted in necrosis of these cells. This is possibly the apoptosis induced by apigenin, which is preceded by secondary necrosis in these cells.
We next quanti®ed the extent of apoptosis by¯ow cytometric analysis of the LNCaP cells labeled with deoxyuridine triphosphate and propidium iodide. The cells were treated with 1 ± 20 mM of apigenin for 24 h. As shown by data in Figure 9 , apigenin treatment resulted in 10.1, 13.8, and 17.3% of apoptotic cells at 5, 10, and 20 mM (Figure 9 ). While the induction of apoptosis was almost negligible (3.2% compared to 1.5% of control) at the lowest dose (1 mM), the highest dose (20 mM) resulted in a signi®cant increase in apoptosis as determined by¯ow cytometry.
Apigenin alters Bax and Bcl-2 protein expression in LNCaP cells
Since Bax and Bcl-2 play a crucial role in apoptosis, we next studied the dose-and time-dependent eects of apigenin on the constitutive protein levels of Bax and Bcl-2 in LNCaP cells. The Western blot analysis exhibited a signi®cant increase in the protein expression of Bax at 10 and 20 mM concentration of apigenin (Figure 10a ). The time-dependent treatment with 10 mM concentration of apigenin resulted in the stabilization of Bax protein, which was observed up to 48 h post-treatment compared to the basal levels ( Figure 10a ). In sharp contrast, the protein expression of Bcl-2 was signi®cantly decreased by apigenin treatment in a dose-dependent fashion (Figure 10a ). Similar decrease in Bcl-2 protein expression was observed during time-dependent study with 10 mM concentration of apigenin for 24, 48 and 72 h ( Figure  10a) . A signi®cant dose-and time-dependent shift in the ratio of Bax to Bcl-2 was observed after apigenin treatment indicating the induction of apoptotic process (Figure 10b ).
Apigenin inhibits constitutive-NF-kB expression in LNCaP cells
In the next series of experiment we investigated the eect of apigenin on the constitutive expression of NFkB/p65 and IkBa in LNCaP cells. Number of studies suggests the role of NF-kB in cell survival by inhibiting apoptosis (Liang et al., 1999; Ahmad et al., 2000) . Employing immunoblot analysis, we investigated the eect of apigenin (1 ± 20 mM concentration for 24 h) on the constitutively expressed NF-kB/p65 in the nuclear fractions obtained from the cells. As shown by immunoblot analysis (Figure 11a ), apigenin treatment resulted in a dose-and time-dependent inhibition of NF-kB/p65 protein expression in these cells. Almost similar results were observed in the cytosolic fractions of cells treated with apigenin (data not shown). The inhibition of NF-kB in the nuclear fraction correlated with the increase in the protein expression of IkBa in Figure 5 Eect of apigenin on the DNA cell cycle analysis in synchronized LNCaP cells. The cells were synchronized in G0 phase by depleting the nutrients for 36 h (referred as control) and replating at sub con¯uent densities into complete medium containing vehicle or apigenin (1, 5, 10 and 20 mM concentration) for 24 h, stained with PI (50 mg/ml) and analysed by¯ow cytometry. Percentage of cells in G0 ± G1, S and G2-M phase were calculated using cell-®t computer software and are represented in the right side of the histograms. The details are described under Materials and methods the cytosol both in dose-and time-dependent fashion ( Figure 11a ). These results were further con®rmed by a more sensitive method that can detect NF-kB and recognize an epitope on p65 by ELISA (Figure 11b ).
Discussion
Flavonoids are naturally occurring plant polyphenols found in abundance in diets rich in fruits, vegetables and plant-derived beverages (Birt et al., 1998; Duthie and Crozier, 2000; Middleton, 1984) . In particular, apigenin, the most common¯avonoid present in plant sources has been shown to possess cancer chemopreventive eects in cell culture system as well as in rodent skin carcinogenesis models (Yin et al., 1999 (Yin et al., , 2001 Wang et al., 2000; Caltagirone et al., 2000; Takahashi et al., 1998; Fotsis et al., 1998; Kuo et al., 1992 Kuo et al., , 1994 Wei et al., 1990; Chaumontet et al., 1994; Panes et al., 1996; Birt et al., 1997; Lepley et al., 1996; Lepley and Pelling, 1997; Liang et al., 1999) . Recently, we have shown the selective growth inhibitory and apoptotic response of apigenin in human prostate carcinoma but not in normal cells (Gupta et al., 2001) . Extending these studies here we have provided the molecular basis by which apigenin may exert its cancer chemopreventive eects on androgen-responsive human prostate carcinoma LNCaP cells. LNCaP cells are unique in vitro model to study human prostate cancer as they possess an aneuploid male karyotype and secrete PSA (Lee et al., 1995) . As most of the molecular mechanisms for the development of prostate cancer involve modulation in the functions of androgen receptor and its signaling pathways we studied the eect of apigenin in inhibiting the AR protein expression and its subsequent eect on PSA production. Our results indicate that apigenin signi®cantly decreases serum-induced AR protein expression in these cells.
Expression of PSA protein has been shown to correlate with¯uctuating androgen levels during male development (Lamb et al., 2001) . PSA belongs to the member of the kallikerin family, is a serine protease synthesized by prostate epithelial cells (Naz and Herness, 2001) . PSA is currently the most accepted marker for assessment of prostate cancer progression in humans and is being detected in the serum of patients with prostate diseases including prostatitis, benign prostatic hypertrophy and prostate cancer (Stamey et al., 1987) . Studies have demonstrated that the expression of PSA glycoprotein and mRNA in LNCaP cells are regulated by androgens via the androgen receptor (Lee et al., 1995; Henttu et al., 1990) . Further, PSA has been reported to cleave the seminal vesicle protein that may augment the activation of growth factors leading to tumor progression (Wang et al., 1997; Henttu et al., 1990 ). Our studies demonstrate a signi®cant decrease in intracellular as well as secreted levels of PSA by apigenin, suggesting that this may be an important strategy to prevent prostate cancer progression.
The cell growth and proliferation of mammalian cells are mediated via cell cycle progression. In recent years, studies have shown an association between cell cycle regulation and cancer, and inhibition of the cell cycle has become an appreciated target for management of cancer (Pucci et al., 2000; Sandhu and Slingerland, 2000) . Our studies indicate that apigenin exerts strong growth inhibitory eects on human prostate carcinoma cells by perturbation in G1?S phase of the cell cycle. The passage through the cell cycle, in eukaryotes is orchestrated by the function of a family of protein kinase complexes. Each complex is composed minimally of a catalytic subunit, the cdk, and its essential activating partner, the cyclins (Pestell et al., 1999) . Cyclins D and E are involved during G 1 ?S phase of the cell cycle. In controlled cell growth, association of cyclins D and E with cdk2, 4 or 6 leads to phosphorylation of Rb; hyperphosphorylated Rb leads to its release from E2F. The free E2F then activates c-myc, resulting in progression of the cell cycle and cellular proliferation. Evidences indicate that overexpression of cyclin D is associated with various cancers and tumor-derived cell lines The cells were treated with vehicle alone or speci®ed concentration of apigenin for 24 h. The ApopNexin apoptosis detection kit (Oncor) was used for the detection of apoptotic and necrotic cells. Apoptosis and necrosis was detected by the kit according to the vendor's protocol using a Zeiss Axiovert 100 microscope. The samples were excited at 330 ± 380 nm, and the image was observed and photographed under a combination of a 400 nm dichoric mirror and then 420-nm high pass ®lter. The details are described under Materials and methods Figure 9 Eect of apigenin on quantitation of apoptosis in LNCaP cells. The cells were treated with apigenin (1 ± 20 mM for 24 h), labeled with deoxyuridine triphosphate using terminal deoxynucleotide transferase and PI by using apoptosis kit obtained from Phoenix Flow Systems (San Diego, CA, USA) as per vendor's protocol followed by¯ow cytometry. Cells showing deoxyuridine triphosphate¯uorescence above that of control population, as indicated by the line in each histogram, are considered as apoptotic cells and their percentage population is shown in each box. The details are described under Materials and methods leading to the uncontrolled growth (Motokura and Arnold, 1993) . One of the aspects of cyclin D overexpression in cells is a shorter G 1 phase, resulting in a more rapid entry into S phase and increased proliferation (Mueller et al., 1997) . Based on these and other studies (Yin et al., 2001; Wang et al., 2000; Lepley et al., 1996; Lepley and Pelling, 1997) , a signi®cant decrease in protein levels of cyclins D1, D2 and E, cdk2, 4 and 6 by apigenin suggests that apigenin is a promising agent for prevention and therapy of prostate cancer. The observed inhibitory eects of apigenin particularly on cyclin D1, cdk2, and cdk4 in LNCaP cells are of particular signi®cance for the intervention of hormone-responsive prostate cancer because cyclin D is strongly associated with androgen-stimulated growth of LNCaP cells. During the progression of the cell cycle, the cdk-cyclin complexes are inhibited via binding to ckis such as CIP/KIP and INK4 families of proteins (Vidal and Ko, 2000) . Because our studies have demonstrated that apigenin treatment of LNCaP cells resulted in a G1 phase arrest of the cell cycle, we examined the eect of apigenin on ckis operative in this phase of the cell cycle. Our data demonstrated a signi®cant upregulation of the WAF1/p21 and KIP1/p27 during G1 phase arrest of LNCaP cells which may be an important molecular mechanism through which apigenin inhibits the growth of cancer cells.
The tumor suppressor gene p53 is regarded as a key element in maintaining a balance between cell growth and cell death in the living system (Agarwal et al., 1998; Pucci et al., 2000; Vidal and Ko, 2000) . The p53, in response to DNA damage, triggers a variety of cell cycle regulatory events to limit the proliferation of damaged cells (Vogelstein et al., 2000) . This`gate keeper' gene, in a number of human tumors, is inactivated by mutation resulting in uncontrolled cellular proliferation (Navone et al., 1993) . Generally, no correlation between p53 mutations and early stage prostate cancer has been noticed but p53 mutations are shown to be associated with a small group (10 ± 20%) of advanced prostate cancer patients with high Gleason score and distant metastasis (Navone et al., 1993; Meyers et al., 1998) . It is, therefore, important to study the role of p53 in tumor growth inhibition and Eect of apigenin on NF-kB activation. The cells were treated with vehicle only or speci®ed concentrations of apigenin for 24 h and then processed for nuclear lysate. NF-kB activation was determined by ELISA Trans-AM kit from Active Motif North America (Carlsbad, CA, USA) for assay of NF-kB/p65 activity. The details are described under Materials and methods. The data represents the mean+s.e. of two experiments each conducted in duplicate induction of apoptosis. Our data showed that apigenin treatment resulted in a signi®cant accumulation and/or stabilization of p53 protein in a dose-and timedependent fashion in LNCaP cells that harbor wildtype p53. The induction of WAF1/p21, along with stabilization of p53 therefore, appears to be p53-dependent in LNCaP cells (with wild-type p53). Studies have indicated an increase in wild-type p53 stability and transactivational activity by apigenin that may be responsible for its anti-tumorigenic activity by stimulating the p53-WAF1/p21 response pathway (McVean et al., 2000) . Studies have established that pRb is capable of exerting growth suppressive activity because of its interaction with E2F/DP heterodimers, which function to trigger the transcription of genes required for cell cycle progression (Adams, 2001; Ahmad et al., 1999) . Since the phosphorylation of pRb is an important event for the progression of cell cycle at G1?S transition (Masciullo et al., 2000) in the present study, we investigated the protein level and the phosphorylation pattern of pRb during apigeninmediated cell cycle arrest and apoptosis. Our results demonstrated dose-as well as time-dependent decrease in the level of hyper-phosphorylated form ppRb and increase in hypo-phosphorylated form or pRb by apigenin and also a decrease in phosphorylation of pRb at serine-780. These series of events results in arrest of cells at G0 ± G1 phase of the cell cycle that may subsequently lead to apoptotic cell death.
Among the number of pathways that can be exploited for cancer prevention and treatment, apoptosis is a physiological process by which cells are removed when an agent damages their DNA. In recent years the concept of cell cycle-mediated apoptosis is also gaining increasing attention and is an ideal way of cell elimination (Pucci et al., 2000; Zornig et al., 2001) . In this regard apigenin is a promising agent as it is capable of selective/preferential elimination of cancer cells by inhibiting cell cycle progression and/or causing apoptosis (Gupta et al., 2001) . Our data demonstrated that apigenin results in the apoptosis of androgenresponsive LNCaP cells. This observation was veri®ed by DNA fragmentation, PARP-cleavage,¯uorescence microscopy and¯ow cytometry. Collectively, these results clearly suggest that apigenin inhibits the growth of prostate carcinoma cells via cell cycle arrest and induces apoptosis, and that these results corroborate the ®ndings of many published studies in several other types of human carcinoma cells (Yin et al., 1999 (Yin et al., , 2001 Wang et al., 2000; Caltagirone et al., 2000; Takahashi et al., 1998) . This could be an important observation that may be useful for devising strategies for the management of human prostate cancer.
Recent studies have indicated that apigenin also functions as a potent inhibitor of the oxidant-and tumor promoter-mediated activation of NF-kB in cell culture system (Liang et al., 1999) . NF-kB is a widely distributed pleiotropic nuclear factor that is known to regulate the expression of genes encoding cytokines, cellular adhesion molecules, and growth factors (Bours et al., 2000) . Studies have also indicated that NF-kB promotes cell survival by inhibiting apoptosis (Bours et al., 2000) . Recently, it has been shown that the downmodulation of NF-kB activity in the cytosol and nucleus is associated with an apoptotic response of the eukaryotic cells (Ahmad et al., 2000) . In recent years, NF-kB has been increasingly appreciated as a target for anticancer drug treatment (Lee and Burckart, 1998) . Our results demonstrate a dose-and timedependent decrease in the constitutive expression of NF-kB/p65 in the cytosol and nucleus with subsequent increase in the protein expression of IkBa in the cytosol by treatment with apigenin. We postulate that apigenin-mediated down-modulation of NF-kB activity could lead to inhibition of cell growth and induction of apoptosis, which are mediated by alterations in the G1-phase of the cell cycle.
Members of the Bcl-2 family of proteins are critical regulators of the apoptotic pathway (Yin et al., 1994) . Bcl-2 is an upstream eector molecule in the apoptotic pathway and is identi®ed as a potent suppressor of apoptosis (Hockenbery et al., 1993) . Bcl-2 is found at inappropriately high levels in more than half of all human tumors (Reed, 1995) . Bcl-2 has been shown to form a heterodimer with the pro-apoptotic member Bax and might thereby neutralize its pro-apoptotic eects. Therefore, alterations in the levels of Bax and Bcl-2, i.e. the ratio of Bax/Bcl-2 is a decisive factor and plays an important role in determining whether cells will undergo apoptosis under experimental conditions that promote cell death. In our study, a decrease in Bcl-2 protein expression was observed in androgenresponsive LNCaP cells. Importantly, the protein expression of Bax, however, was up-regulated in LNCaP cells after treatment up to 72 h, hence the ratio of Bax to Bcl-2 was altered in favor of apoptosis. Our results suggest that up-regulation of Bax and down-modulation of Bcl-2 may be another molecular mechanism through which apigenin induces apoptosis. Based on the outcome of this study and the available literature knowledge, as shown in the composite scheme in Figure 12 , we suggest multiple pathways by which apigenin results in apoptotic cell death. This may be mediated via cell cycle arrest, modulation in Bax/Bcl-2 ratio or NF-kB pathway. It is important to mention here, that based on the daily dietary consumption of¯avonoids, the concentration used in our present study is physiologically achievable in humans (Hollman and Katan, 1999a) . This may, in part, be supported by the epidemiological observations that regular consumption of fruits and vegetables, particularly cruciferous vegetables rich in¯avonoids, may reduce the risk of prostate cancer (Kolonel et al., 2000; Cohen et al., 2000) . Studies also indicate that these associations remain inconclusive because the chemopreventive eects achieved by¯avonoids have often not been observed in in vivo situations (Hollman and Katan, 1999b) . Therefore, more detailed case ± control design studies are required to validate these ®ndings.
Our study provides an in-depth experimental evidence for the ®rst time that apigenin, the most common and abundantly distributed¯avonoid in the plant kingdom, inhibits both serum-and androgenstimulated PSA protein levels in LNCaP cells concomitant with cell growth inhibition via G1-phase arrest and apoptosis. Further, detailed mechanistic studies are required to de®ne the eect of apigenin on several other human prostate carcinoma cells, especially on hormone-unresponsive cells at molecular levels and to assess the inhibitory eects in in vivo models of prostate cancer. In summary, however, based on the present ®ndings it is tempting to suggest that apigenin has strong potential for development as a chemopreventive and possibly as a therapeutic agent against prostate cancer.
Materials and methods
Materials
Apigenin (595% purity) was obtained from Sigma Chemical Co. (St. Louis, MO, USA). The mono-and poly-clonal antibodies (human reactive anti-AR, PSA, cdk2, 4 and 6, WAF1/p21, KIP1/p27, p53, pRb) were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The human reactive monoclonal and polyclonal antibodies for anticyclins D1, D2 and E were obtained from Neomarker (Fremont, CA, USA). The other human reactive monoclonal and polyclonal antibodies for anti-PARP, Bax, Bcl-2, NF-kB/ p54 and IkBa were purchased from Upstate Biotechnology (Lake Placid, NY, USA) while the anti-Ser780-phospho-Rb was obtained from MBL, Ltd. (Naka-ku Nagoya, Japan).
Cell culture and treatments
The human prostate carcinoma LNCaP cells were obtained from American Type Culture Collection (Manassas, VA, USA) and cultured in RPMI 1640 medium (Gibco, Rockville, MD, USA), supplemented with 10% FBS, 1% penicillin/ streptomycin (P-S) in a 5% CO 2 atmosphere at 378C. LNCaP cells were also cultured in 10% charcoal-stripped FBS (cFBS) and 1% P-S with or without DHT.
Cell viability
The eect of apigenin on the viability of cells was determined by ]-2,5-diphenyl tetrazoliumbromide) assay. The cells were plated at 1610 4 cells per well in 200 ml of complete culture medium containing 1, 5, 10, 20, 40 and 80 mM concentrations of apigenin in 96-well microtiter plates for 24, 48 and 72 h, respectively. Apigenin stock solutions were prepared in dimethyl sulfoxide (DMSO) at 10 mM concentration, and mixed with fresh medium to achieve the desired ®nal concentration. Each concentration of apigenin was repeated in 10 wells. After incubation for speci®ed time at 378C in a humidi®ed incubator, cell viability was determined. MTT (5 mg/ml in phosphate buered saline) was added to each well and incubated for 2 h after which the plate was centrifuged at 1800 g for 5 min at 48C. The MTT solution was removed from the wells by aspiration. After careful removal of the medium, 0.1 ml of buered DMSO was added to each well, and plates were shaken. The absorbance was recorded on a microplate reader at the wavelength of 540 nM. The eect of apigenin on growth inhibition was assessed as per cent cell viability where vehicle-treated cells were taken as 100% viable. 
DNA cell cycle analysis
The cells (70% con¯uent) were starved for 36 h to arrest them in G0 phase of the cell cycle, after which they were treated with apigenin (1, 5, 10 and 20 mM doses) in RPMI-1640 complete media for 24 h. The cells were trypsinized thereafter, washed twice with cold PBS, and centrifuged. The pellet was resuspended in 50 ml cold PBS and 450 ml cold methanol for 1 h at 48C. The cells were centrifuged at 110 g for 5 min, pellet washed twice with cold PBS, suspended in 500 ml PBS, and incubated with 5 ml RNAse (20 mg/ml ®nal concentration) at 378C for 30 min. The cells were chilled over ice for 10 min and stained with propidium iodide (50 mg/ml ®nal concentration) for 1 h and analysed by¯ow cytometry.
Protein extraction and Western blotting
The cells (70% con¯uent) were treated with apigenin (1, 5, 10 and 20 mM doses) in RPMI-1640 complete media for 24 h. For time-dependent assay, the cells (50 ± 60% con¯uent) were treated for 24, 48 and 72 h with 10 mM of apigenin. After which the media was aspirated, the cells were washed with cold PBS (10 mM, pH 7.4) and ice-cold lysis buer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 20 mM NaF, 100 mM Na 3 VO 4 , 0.5% NP-40, 1% Triton X-100, 1 mM PMSF (pH 7.4)) with freshly added protease inhibitor cocktail (Protease Inhibitor Cocktail Set III, Calbiochem, La Jolla, CA, USA) over ice for 30 min. The cells were scraped, the lysate was collected in a microfuge tube and passed through a 21 G needle to break up the cell aggregates. The lysate was cleared by centrifugation at 14 000 g for 15 min at 48C and the supernatant (total cell lysate) was used or immediately stored at 7808C. For NF-kB/p65 assay the cells were processed for cytosolic and nuclear fractions as described previously (Ahmad et al., 2000) . The protein concentration was determined by DC Bio-Rad assay using the manufacturer's protocol (Bio Rad Laboratories, Hercules, CA, USA). For Western blotting, 25 ± 50 mg protein was resolved over 8 ± 12% polyacrylamide gels and transferred to a nitrocellulose membrane. The blot was blocked in blocking buer (5% nonfat dry milk/1% Tween 20; in 20 mM TBS, pH 7.6) for 1 h at room temperature, incubated with appropriate monoclonal or polyclonal primary antibody in blocking buer for 1 h to overnight at 48C, followed by incubation with anti-mouse or anti-rabbit secondary antibody horseradish peroxidase conjugate obtained from Amersham Life Science Inc. (Arlington Height, IL, USA) and detected by chemiluminescence and autoradiography using XAR-5 ®lm obtained from Eastman Kodak Co. (Rochester, NY, USA). Densitometric measurements of the bands in Western blot analysis were performed using digitalized scienti®c software program UN-SCAN-IT purchased from Silk Scienti®c Corporation (Orem, UT, USA).
DNA fragmentation assay
The cells were grown to about 70% con¯uence and treated with apigenin (1, 5, 10 and 20 mM concentration) for 48 h. Following this treatment, the cells were washed twice with phosphate-buered saline (10 mM Tris, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , and 0.5% Triton X-100), left on ice for 15 min, and pelleted by centrifugation (14 000 g) at 48C. The pellet was incubated with DNA lysis buer (10 mM Tris, pH 7.5, 400 mM NaCl, 1 mM EDTA, and 1% Triton X-100) for 30 min on ice and then centrifuged at 14 000 g at 48C. The supernatant obtained was incubated overnight with RNAse (0.2 mg/ml) at room temperature and then with Proteinase K (0.1 mg/ml) for 2 h at 378C. DNA was extracted using phenol : chloroform (1 : 1) and precipitated with 95% ethanol for 2 h at 7808C. The DNA precipitate was centrifuged at 14 000 g at 48C for 15 min and the pellet was air-dried and dissolved in 20 ml of Tris-EDTA buer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA). Total amount of DNA was resolved over 1.5% agarose gel, containing 0.3 mg/ml ethidium bromide in 16TBE buer (pH 8.3, 89 mM Tris, 89 mM Boric acid and 2 mM EDTA) (Bio Wittaker, Inc., Walkersville, MD, USA). The bands were visualized under UV transilluminator (Model # TM-36, UVP Inc., San Gabriel, CA, USA) followed by polaroid photography (MP-4 Photographic System, Fotodyne Inc., Hartland, WI, USA).
Apoptosis detection by fluorescence microscopy
The ApopNexin apoptosis detection kit (Oncor, Gaithersburg, MD, USA) was used for the detection of apoptotic cells. This kit uses a dual-staining protocol in which the apoptotic cells are stained with annexin V (green¯uores-cence), and the necrotic cells are stained with propidium iodide (red¯uorescence). Brie¯y, the cells were grown to about 50% con¯uence in 6-well plate and then treated with apigenin (1, 5, 10 and 20 mM concentration) for 24 h. Apoptosis was detected by the use of the kit according to the vendor's protocol using a Zeiss Axiovert 100 microscope. Brie¯y, the samples were excited at 330 ± 380 nm, and the image was observed and photographed under a combination of a 400-nm dichoric mirror and then 420-nm high-pass ®lter. Cells with green, condensed chromatin pattern were scored as apoptotic, whereas those with red nuclei without nuclear condensation were considered necrotic.
Quantification of apoptosis
For quanti®cation of apoptosis, the cells were grown at a density of 1610 6 cells in 100-mm culture dishes and were treated with apigenin (1, 5, 10, and 20 mM concentration) for 24 h. The cells were trypsinized, washed with PBS, and processed for labeling with¯uorescein-tagged deoxyuridine triphosphate nucleotide and propidium iodide by use of an APO-DIRECT apoptosis kit obtained from Phoenix Flow Systems (San Diego, CA, USA) as per manufacturer's protocol. The labeled cells were then analysed by¯ow cytometry.
ELISA assay for PSA and NF-kB activity Enzyme linked immunoabsorbent assay (ELISA) was performed for PSA and NF-kB/p65 activity. The human PSA ELISA kit was obtained from Anogen (Ontario, Canada) for the quantitative determination of PSA in cell lysate and culture medium according to the vendor's protocol. Brie¯y, the kit applies a technique of quantitative sandwich immunoassay for determination of PSA with an estimated sensitivity of 1 ng/ml PSA antigen.
The commercially available Trans-AM kit was obtained from Active Motif North America (Carlsbad, CA, USA) for assay of NF-kB/p65 activity according to the vendor's protocol. Brie¯y, the assay uses an oligonucleotide containing NF-kB consensus site (5'-GGGACTTTCC-3') that binds to the cell extract and can detect NF-kB, which can recognize an epitope on p65 activated and bound to its target DNA. This assay is speci®c for NF-kB activation and is highly sensitive when compared with the gel retardation technique.
Abbreviations PSA, Prostate-speci®c antigen; AR, androgen receptor; NF-kB, nuclear factor-kappa B; pRb, hypo-phosphorylated retinoblastoma; ppRb, hyper-phosphorylated retinoblastoma; DMSO, dimethyl sulphoxide; PBS, phosphate buered saline; TBS, tris buered saline; DHT, 5a-dihydrotestosterone; cdk, cyclin-dependent kinase; cki, cyclin kinase inhibitor.
